Dergiler / The Journal of Breast Health / 2015 / Cilt: 11 - Sayı: 3

Meme Kanseri Tanısı Alan BRCA Mutasyon Taşıyıcılarında Cerrahi Tedavi

Sayfa
101–105
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

ÖZMEN, V. (2015). Meme Kanseri Tanısı Alan BRCA Mutasyon Taşıyıcılarında Cerrahi Tedavi. The Journal of Breast Health, Cilt: 11 - Sayı: 3, 101–105. https://ajindex.com/articles/362652

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R, Thomas S, Howell A; FH02 Study Group; RGC teams, Miedzybrodzka Z, Murray A. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 2014; 16:442. (PMID: 25510853) [CrossRef] 2. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105: 812-822. [CrossRef] 3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329-1333. (PMID: 17416853) [CrossRef] 4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087-2106. (PMID: 16360786) [CrossRef] 5. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non- BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007; 43:867-876. (PMID: 17307353) [CrossRef] 6. Eccles D, Simmonds P, Goddard J, Coultas M, Hodgson S, Lalloo F, Evans G, Haites N. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer 2001, 1:65-72. (PMID: 14573999) [CrossRef] 7. El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, Ditkoff BA, Schnabel F, Mansukhani M. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 2004; 11:157- 164. (PMID: 14761918) [CrossRef] 8. Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A, Farante G, Galimberti V, Luini A, Veronesi P, Bonanni B. Breast conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009; 16:3380-3387. (PMID: 19649554)